TAHO Pharmaceuticals
6467.TWTaipei, Taiwan· Est.
TAHO Pharma delivers novel transdermal and oral‑film drug formats to address unmet patient needs across cardiovascular, neurology, and oncology markets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
TAHO Pharma delivers novel transdermal and oral‑film drug formats to address unmet patient needs across cardiovascular, neurology, and oncology markets.
CardiovascularNeurologyOncologyEmergency Medicine
Technology Platform
Proprietary Transepithelial Delivery System (TDS) enabling transdermal, oral dissolving film, and buccal film formats for sustained or rapid drug absorption without swallowing.
Opportunities
Regulatory approval of TAH3311 could open multi‑billion‑dollar anticoagulant markets in the U.S.
and Europe, while the oral‑film platform can be leveraged for rapid‑action emergency drugs and pediatric formulations.
Risk Factors
Reliance on a limited number of late‑stage assets means that any regulatory setbacks could materially affect revenue timelines; competition from established oral anticoagulants and emerging film technologies may erode market share.
Competitive Landscape
TAHO’s unique TDS platform differentiates it from traditional oral and injectable competitors, but faces competition from other oral‑film developers and transdermal patch manufacturers targeting similar indications.